MRI features of hepatocellular carcinoma related to biologic behavior
- PMID: 25995679
- PMCID: PMC4435980
- DOI: 10.3348/kjr.2015.16.3.449
MRI features of hepatocellular carcinoma related to biologic behavior
Abstract
Imaging studies including magnetic resonance imaging (MRI) play a crucial role in the diagnosis and staging of hepatocellular carcinoma (HCC). Several recent studies reveal a large number of MRI features related to the prognosis of HCC. In this review, we discuss various MRI features of HCC and their implications for the diagnosis and prognosis as imaging biomarkers. As a whole, the favorable MRI findings of HCC are small size, encapsulation, intralesional fat, high apparent diffusion coefficient (ADC) value, and smooth margins or hyperintensity on the hepatobiliary phase of gadoxetic acid-enhanced MRI. Unfavorable findings include large size, multifocality, low ADC value, non-smooth margins or hypointensity on hepatobiliary phase images. MRI findings are potential imaging biomarkers in patients with HCC.
Keywords: Hepatocellular carcinoma; Magnetic resonance imaging; Prognosis.
Figures









Similar articles
-
Gadoxetic acid-enhanced magnetic resonance imaging can predict the pathologic stage of solitary hepatocellular carcinoma.World J Gastroenterol. 2019 Jun 7;25(21):2636-2649. doi: 10.3748/wjg.v25.i21.2636. World J Gastroenterol. 2019. PMID: 31210715 Free PMC article.
-
Gadoxetic acid-enhanced hepatobiliary phase MRI and high-b-value diffusion-weighted imaging to distinguish well-differentiated hepatocellular carcinomas from benign nodules in patients with chronic liver disease.AJR Am J Roentgenol. 2011 Nov;197(5):W868-75. doi: 10.2214/AJR.10.6237. AJR Am J Roentgenol. 2011. PMID: 22021534
-
Hypervascular hepatocellular carcinoma 1 cm or smaller in patients with chronic liver disease: characterization with gadoxetic acid-enhanced MRI that includes diffusion-weighted imaging.AJR Am J Roentgenol. 2011 Jun;196(6):W758-65. doi: 10.2214/AJR.10.4394. AJR Am J Roentgenol. 2011. PMID: 21606265
-
Gadoxetic acid-enhanced magnetic resonance imaging: Hepatocellular carcinoma and mimickers.Clin Mol Hepatol. 2019 Sep;25(3):223-233. doi: 10.3350/cmh.2018.0107. Epub 2019 Jan 21. Clin Mol Hepatol. 2019. PMID: 30661336 Free PMC article. Review.
-
Hepatobiliary MR contrast agents in hypovascular hepatocellular carcinoma.J Magn Reson Imaging. 2015 Feb;41(2):251-65. doi: 10.1002/jmri.24712. Epub 2014 Aug 8. J Magn Reson Imaging. 2015. PMID: 25104398 Review.
Cited by
-
Estimating postsurgical outcomes of patients with a single hepatocellular carcinoma using gadoxetic acid-enhanced MRI: risk scoring system development and validation.Eur Radiol. 2023 May;33(5):3566-3579. doi: 10.1007/s00330-023-09539-7. Epub 2023 Mar 18. Eur Radiol. 2023. PMID: 36933020
-
Texture analysis on gadoxetic acid enhanced-MRI for predicting Ki-67 status in hepatocellular carcinoma: A prospective study.Chin J Cancer Res. 2019 Oct;31(5):806-817. doi: 10.21147/j.issn.1000-9604.2019.05.10. Chin J Cancer Res. 2019. PMID: 31814684 Free PMC article.
-
MRI proton density fat fraction for estimation of tumor grade in steatotic hepatocellular carcinoma.Eur Radiol. 2023 Dec;33(12):8974-8985. doi: 10.1007/s00330-023-09864-x. Epub 2023 Jun 27. Eur Radiol. 2023. PMID: 37368108 Free PMC article.
-
Imaging features of hepatocellular carcinoma in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: a systematic review and meta-analysis.Abdom Radiol (NY). 2022 Jun;47(6):2089-2098. doi: 10.1007/s00261-022-03499-0. Epub 2022 Apr 7. Abdom Radiol (NY). 2022. PMID: 35389074
-
Radiomics and radiogenomics of primary liver cancers.Clin Mol Hepatol. 2019 Mar;25(1):21-29. doi: 10.3350/cmh.2018.1007. Epub 2018 Nov 16. Clin Mol Hepatol. 2019. PMID: 30441889 Free PMC article. Review.
References
-
- Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519–524. - PubMed
-
- Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol. 2005;40:225–235. - PubMed
-
- Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89–95. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials